Biofrontera Group

Biofrontera Group is a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for dermatological conditions. Established with a vision to improve patient outcomes, Biofrontera is dedicated to addressing unmet medical needs in skin health.

The company specializes in photodynamic therapy, particularly for the treatment of actinic keratosis, a common skin condition caused by sun damage. Biofrontera’s flagship product, Ameluz®, is a prescription medication that has been proven effective in clinical trials and is widely used across various markets.

In addition to its commitment to research and development, Biofrontera places a strong emphasis on patient education and support. The company believes that informed patients are better equipped to manage their conditions and make decisions about their treatment options.

With a robust pipeline of products in development, Biofrontera aims to expand its portfolio and reach more patients globally. The company collaborates with healthcare professionals and institutions to ensure that its therapies are accessible and effective.

Biofrontera Group operates with a strong ethical framework, prioritizing safety, efficacy, and quality in all its operations. The company is also committed to sustainability and corporate social responsibility, striving to minimize its environmental impact while contributing positively to society.

Headquartered in the UK, Biofrontera Group is strategically positioned to leverage its expertise and resources to drive innovation in dermatology. The company’s team comprises experienced professionals who are passionate about advancing skin health and improving the lives of patients.

As Biofrontera continues to grow, it remains focused on its mission to be a leader in dermatological therapies, providing solutions that enhance the quality of life for individuals affected by skin conditions.